Suzanne Sirota-Rozenberg, DO
Procedural Dermatology · Woodmere, NYNPI 1841245859
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $100,175 of the $122,114 with a category attached, or 82.0%. Galderma Laboratories, L.p. accounts for 81.9% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $33,626 and has fallen 59.2% since, to $13,725 in 2025.
Across 803 payments — averaging $152.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$100K
- Sanofi$7K
- AbbVie$2K
- Lilly USA, LLC$1K
- Regeneron Healthcare Solutions, Inc.$980
- Johnson & Johnson$908
- plus $9K from 33 others
What the payments were for
- Consulting fees$1,3531%
- Speaking & faculty fees$100,17582%
- Travel & lodging$1,1331%
- Food & beverage$19,13516%
- Education$3190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,114 in reported general payments places this provider in the 85th percentile of 69 procedural dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 18 | $206,987 |
| Dupixent PenDupilumab | 29 | $104,495 |
| OtezlaApremilast | 15 | $71,347 |
| Dupixent SyringeDupilumab | 12 | $43,404 |
| Tacrolimus | 43 | $5,831 |
| Clobetasol Propionate | 73 | $3,561 |
| Ketoconazole | 135 | $2,490 |
| Fluocinonide | 41 | $2,406 |
| Halobetasol Propionate | 17 | $1,648 |
| Clindamycin Phosphate | 34 | $1,473 |
| Metronidazole | 18 | $1,326 |
| Triamcinolone Acetonide | 108 | $1,220 |
| Azelaic Acid | 11 | $1,081 |
| Ammonium Lactate | 42 | $1,065 |
| Doxycycline Hyclate | 37 | $901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $874 | $71,34715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 69 procedural dermatology providers in New York.
Other procedural dermatology in Woodmere
- Joseph SchwartzTroy$470K
- Michelle HenryNew York$460K
- Jerry ShapiroNew York$414K
- Jared JagdeoBrooklyn$362K
- Dendy EngelmanNew York$292K
- Evan RiederNew York$210K
- Daniel Belkin-HollandNew York$208K
- Robert BacigalupiGarden City$109K
- Anthony ChiaravallotiEast Syracuse$90K
- Ariel OstadNew York$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.